🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

John S. Schardt

AstraZeneca (Singapore)

ORCID: 0000-0002-5605-4732

Also affiliated with AstraZeneca (Brazil), AstraZeneca (Japan)

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 11 papers. Top paper: “Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space”.

Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space

Nature Communications(2022)10.1038/s41467-022-31457-3

N/A

4.2DataRank · unranked

160 citations

Patrick C. Kinnunen, Jie Huang, Lina Wu, Matthew D. Smith, Tiexin Wang +8 more

Engineered Multivalent Nanobodies Potently and Broadly Neutralize SARS‐CoV‐2 Variants

Advanced Therapeutics(2021)10.1002/adtp.202100099

N/A

1.3DataRank · unranked

44 citations

John S. Schardt, Alec A. Desai, Emily K. Makowski, Matthew D. Smith, Ghasidit Pornnoppadol +5 more

Agonist antibody discovery: Experimental, computational, and rational engineering approaches

Drug Discovery Today(2021)10.1016/j.drudis.2021.09.008

N/A

0.510DataRank · unranked

29 citations

Harkamal S. Jhajj, Ryen L. O'Meara, Timon S. Lwo, Matthew D. Smith, Peter M. Tessier +1 more

Monoclonal Antibody Generation Using Single B Cell Screening for Treating Infectious Diseases

BioDrugs(2024)10.1007/s40259-024-00667-0

N/A

0.457DataRank · unranked

20 citations

Neelan S Sivaneri, Peter M. Tessier, John S. Schardt

Optimization of therapeutic antibodies for reduced self-association and non-specific binding via interpretable machine learning

Nature Biomedical Engineering(2023)10.1038/s41551-023-01074-6

N/A

0DataRank · unranked

48 citations

Tiexin Wang, Jennifer M. Zupancic, Jie Huang, Lina Wu, John S. Schardt +5 more

Facile generation of biepitopic antibodies with intrinsic agonism for activating receptors in the tumor necrosis factor superfamily

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.12.11.571146

N/A

0DataRank · unranked

0 citations

John S. Schardt, Namir Khalasawi, Emily L. Yao, Timon S. Lwo, Na-Young Kwon +4 more

Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis

Cell chemical biology(2021)10.1016/j.chembiol.2021.05.019

N/A

0DataRank · unranked

59 citations

Alec A. Desai, John S. Schardt, Ghasidit Pornnoppadol, Emily K. Makowski, Matthew D. Smith +7 more

Facile generation of biepitopic antibodies with intrinsic agonism for activating tumor necrosis factor receptors

Cell chemical biology(2024)10.1016/j.chembiol.2024.03.010

N/A

0DataRank · unranked

5 citations

John S. Schardt, Namir Khalasawi, Emily L. Yao, Timon S. Lwo, Na-Young Kwon +4 more

Discovery and characterization of high-affinity, potent SARS-CoV-2 neutralizing antibodies via single B cell screening

Scientific Reports(2021)10.1038/s41598-021-99401-x

N/A

0DataRank · unranked

25 citations

Ghasidit Pornnoppadol, Alec A. Desai, Kyung Soo Park, Jennifer M. Zupancic, Emily K. Makowski +8 more

Improving antibody drug development using bionanotechnology

Current Opinion in Biotechnology(2021)10.1016/j.copbio.2021.10.027

N/A

0DataRank · unranked

11 citations

John S. Schardt, Peter M. Tessier, Emily K. Makowski

Mutational analysis of SARS-CoV-2 variants of concern reveals key tradeoffs between receptor affinity and antibody escape

PLoS Computational Biology(2022)10.1371/journal.pcbi.1010160

N/A

0DataRank · unranked

22 citations

John S. Schardt, Matthew D. Smith, Peter M. Tessier, Emily K. Makowski